Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Up 47.1% in July

Hookipa Pharma Inc (NASDAQ:HOOK) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 95,300 shares, an increase of 47.1% from the June 30th total of 64,800 shares. Based on an average daily volume of 86,400 shares, the short-interest ratio is currently 1.1 days. Currently, 1.2% of the shares of the stock are sold short.

Hookipa Pharma Stock Performance

Shares of NASDAQ HOOK traded down $0.45 during midday trading on Monday, reaching $5.70. 27,724 shares of the stock were exchanged, compared to its average volume of 69,304. The company has a 50 day simple moving average of $7.01 and a 200 day simple moving average of $7.29. The stock has a market capitalization of $56.40 million, a P/E ratio of -1.14 and a beta of 0.81. Hookipa Pharma has a twelve month low of $4.10 and a twelve month high of $11.30.

Hookipa Pharma (NASDAQ:HOOK) last announced its quarterly earnings results on Thursday, May 9th. The company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.20) by $2.40. The business had revenue of $36.60 million during the quarter, compared to the consensus estimate of $3.20 million. Hookipa Pharma had a negative net margin of 88.73% and a negative return on equity of 33.33%. During the same quarter last year, the firm earned ($2.70) EPS. On average, research analysts expect that Hookipa Pharma will post -2.57 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on HOOK. HC Wainwright upped their price target on shares of Hookipa Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, June 5th. JMP Securities reduced their price target on shares of Hookipa Pharma from $50.00 to $23.00 and set a “market outperform” rating for the company in a research report on Friday. Finally, Royal Bank of Canada restated an “outperform” rating and set a $50.00 price target on shares of Hookipa Pharma in a research report on Tuesday, May 21st.

Hedge Funds Weigh In On Hookipa Pharma

A hedge fund recently raised its stake in Hookipa Pharma stock. Acadian Asset Management LLC raised its holdings in Hookipa Pharma Inc (NASDAQ:HOOK) by 85.8% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 882,262 shares of the company’s stock after buying an additional 407,532 shares during the period. Acadian Asset Management LLC owned approximately 0.89% of Hookipa Pharma worth $627,000 as of its most recent SEC filing. 63.88% of the stock is currently owned by hedge funds and other institutional investors.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.